Biotechnology CTO Programming 
GeekWire
AUGUST 2, 2024
Sana Biotechnology CEO Steve Harr cuts the ribbon at the company’s new manufacturing facility in Bothell, Wash., Suzan DelBene, Bothell Mayor Mason Thompson, and Sana CTO Snehal Patel also participated in the ceremony. The Bothell facility will house Sana’s proprietary cancer drug program. Washington state Rep.
GeekWire
APRIL 11, 2023
Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies , the company said today in a regulatory filing. He was first hired by Adaptive as chief technology officer. Sana Biotechnology named two new research leaders. Mark Adams.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeekWire
APRIL 3, 2024
F5 Chief People Officer Lyra Schramm (left) and Chief Technology Officer Kunal Anand. (F5 F5 Photos) — Seattle-based application security and delivery giant F5 announced two new executive appointments this week: Lyra Schramm , the company’s new chief people officer, and Kunal Anand , chief technology officer.
GeekWire
OCTOBER 20, 2020
The founding team includes: • CEO Peter Horadan, previously EVP of engineering and CTO at tax automation startup Avalara. Chief Strategy Officer Matthew Shanahan , previously chief operating and innovation officer at Globys, a software company offering digital billing products. Nautilus Biotechnology Photo).
GeekWire
NOVEMBER 21, 2024
Helping people in all stages Now, Pultz is the chief technology officer at Mopac, another company born from the IPD and UW ingenuity. She was on the forefront of the biotechnology future. KumaMax is currently in phase two of clinical trials, meaning it’s one step closer to making gluten intolerance less intolerable.
GeekWire
MARCH 10, 2023
The news is a bright spot for Seattle’s biopharma scene which has seen employee cuts at several biotech companies recently as part of wider layoffs in the industry, including at NanoString Technologies , Sana Biotechnology , Eliem Therapeutics and Neoleukin Therapeutics. It reported $19.3 billion in revenue for 2022, up from $18.5
GeekWire
DECEMBER 27, 2022
He’s now CEO of Nautilus Biotechnology, and he’s not taking any big chances in the current economic downturn. Earlier companies are considering fewer development programs and having a slower ramp on hiring. Neoleukin Therapeutics recently shed staff in the wake of disappointing clinical data for its lead program, for example.
Expert insights. Personalized for you.
116 
Let's personalize your content